ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K and RB pathways. Within the MAPK pathway ERK1/2 proteins exert a bottleneck function for transmitting mitogenic signals and activating cytoplasmic...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Cancer Ther
Prif Awduron: Köhler, Jens, Zhao, Yutong, Li, Jiaqi, Gokhale, Prafulla C., Tiv, Hong L., Knott, Aine R., Wilkens, Margaret K., Soroko, Kara M., Lin, Mika, Ambrogio, Chiara, Musteanu, Monica, Ogino, Atsuko, Choi, Jihyun, Bahcall, Magda, Bertram, Arrien A., Chambers, Emily S., Paweletz, Cloud P., Bhagwat, Shripad V., Manro, Jason R., Tiu, Ramon V., Jänne, Pasi A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026682/
https://ncbi.nlm.nih.gov/pubmed/33536188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0531
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg